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Abstract
This article discusses seven issues in the management of hypertension in diabetic patients, namely the importance of blood 
pressure control, optimal blood pressure control levels, the importance of blocking the renin-angiotensin system, the inevi-
tability of combination anti-hypertensive therapy, drug choices, the diabetogenic effects of high dose thiazide diuretics and 
beta-blockers and the importance of treating other risk factors, like dyslipidaemia. 
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INTRODUCTION
Diabetes mellitus and hypertension are 
common clinical conditions that often 
co-exist.  This combination has been 
called “the deadly duet” to emphasise 
the increased cardiovascular risk that 
is associated with the combination of 
these two conditions. 1 Hypertension 
also occurs more commonly in diabet-
ics than in non-diabetics.2
The prevalence of hypertension in 
diabetics is about two times higher 
than the prevalence of hypertension 
as observed in the general population.3 
In type 2 diabetes mellitus (T2DM), hy-
pertension is often present as part of 
an underlying metabolic syndrome or 
insulin resistance syndrome.   In type 
1 diabetes mellitus (T1DM), however, 
hypertension is often due to diabetic 
nephropathy.
Hypertensive patients are 2.5 times 
more likely to develop diabetes mel-
litus within 5 years after the onset of 
hypertension.4  This may be due to the 
presence of an underlying metabolic 
syndrome or may, additionally, be due 
to the type of antihypertensive drug 
used (e.g. high dose thiazides com-
bined with high-dose beta-blockers 
especially atenolol).
The co-existence of hypertension and 
diabetes mellitus greatly increases the 
risk for macrovascular and microvas-
cular complications.  In patients with 
diabetes, the presence of hypertension 
causes a 7.2-fold increase in mortality 
and in diabetic nephropathy, the pres-
ence of hypertension causes a 37-fold 
increase in mortality.5
Most of the patients with diabetes and 
hypertension will die from a cardiovas-
cular cause.  Hypertension exacerbates 
all the vascular complications of diabe-
tes including coronary artery disease, 
renal disease, stroke, peripheral artery 
disease, leg amputations and reti-
nopathy.  Diabetes increases the risk 
of coronary artery disease - two-fold in 
men and four-fold in women. Women 
are, therefore, at particular risk.
MANAGEMENT PRINCIPLES:
I Blood pressure control is crucial
Data from clinical trials emphasise the 
need for tight blood pressure control 
in patients with diabetes and hyperten-
sion.
In the UK Prospective Diabetes Study 
(UKPDS) each 10mmHg decrease in 
mean systolic blood pressure was as-
sociated with a risk reduction of 12% 
for any complication related to diabe-
tes, a risk reduction of 15% of deaths, 
a risk reduction of 11% for myocardial 
infarction and a risk reduction of 13% 
for microvascular complications.6 There 
was no threshold where risk was not 
observed.
II What is the Blood Pressure goal?
Both the UKPDS and HOT-trials (Hy-
pertension Optimal Treatment) demon-
strated improved outcomes in patients 
assigned to lower blood pressure tar-
gets.  Epidemiological analyses show 
that blood pressure measurements 
≥120/70mmHg are associated with 
increased cardiovascular event rates 
and mortality in patients with diabe-
tes.  A target blood pressure goal < 
130/80mmHg is both reasonable and 
safe to achieve.  Achieving lower levels 
will decrease risk, but can be difficult 
to achieve and will increase the cost of 
treatment and the side-effect profile.5 
Control of especially systolic blood 
pressure is important.
III The need for multiple-drug therapy
Evidence shows that to achieve the 
set goal of < 130/80mmHg, requires 
the use of multiple-drug antihyperten-
sive therapy.  Agents should be used 
that have been shown to reduce car-
diovascular risk while not worsening 
concomitant conditions (e.g. new onset 
diabetes, abnormal lipids).
IV Blockade of the renin-angiotensin 
system (RAS)
Agents blocking RAS, such as angio-
tensin-converting enzyme inhibitors 
(ACE-I) and angiotensin receptor 
blockers (ARB’s), should be one of 
the partner drugs used in combination 
in hypertensive patients with diabetes 
or glucose intolerance.7  These drugs 
(ACE-I and ARB’s) are also important 
to use if there are any microalbuminuria 
or proteinuria present as they reduce 
the progression to end-stage renal dis-
ease.  The evidence is especially im-
pressive with ARBs.  Other drugs have 
also been shown to reduce proteinuria 
(e.g. indapamide and non-dehidrop-
iridine calcium channel blockers, like 
verapamil).
V Which drug to use?
Clinical trials with diuretics, beta-block-
ers, ACE-inhibitors, angiotensin recep-
tor blockers (ARB) and calcium chan-
nel antagonists have all demonstrated 
benefit in the treatment of hypertension 
in type I diabetes mellitus as well as 
type 2 diabetes mellitus.8 This is re-
lated to the degree of blood pressure 
lowering. The question of which drug 
is superior has not clearly been an-
swered, but is probably not necessary 
to answer, because the hypertensive 
diabetic will require two or more drugs 
to reach the lower target blood pres-
sure.  It is also important to evaluate the 
patients for either known complications 
(e.g. coronary artery disease or other 
concomitant disease) to decide on the 
best combination of drugs.
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The Blood Pressure Lowering Treat-
ment Trialist Collaboration published a 
meta-analysis of 27 randomised trials 
with 158,709 patients to evaluate the 
effect of blood-pressure lowering on 
major cardiovascular events in patients 
with and without diabetes mellitus.9 The 
results from this meta-analysis dem-
onstrated that major cardiovascular 
events were reduced to a comparable 
extent in individuals with and without 
diabetes by regimens based on an-
giotensin-converting enzyme inhibitors 
(ACE-I), calcium antagonists, angio-
tensin receptor blockers (ARB) and di-
uretic-beta blocker combinations.  This 
effect was for short-to medium term 
duration.  There is no data for long-term 
event reduction.  The data also did not 
evaluate specific indications for spe-
cific drug groups.
The implications of this meta-analy-
sis clearly demonstrate that there are 
no particular drug or drugs that are su-
perior in diabetes and that the majority 
of patients will in any case require two 
or more drugs to achieve goal blood 
pressure.
VI New-onset diabetes and the use of 
antihypertensive drugs
People with elevated blood pressure 
levels are 2.5 times more likely to de-
velop diabetes mellitus within 5 years 
than people with normal blood pres-
sure levels.  This phenomenon is made 
worse by the chronic administration of 
diuretics and beta-blockers, especially 
when administered in combinations 
with high doses.11 The issue is currently 
hotly debated in the literature as to the 
exact mechanism and clinical implica-
tions.  There is no question that the dys-
metabolic effects of diuretics and beta-
blockers are dose dependent.  There 
is indirect trial evidence that diuretics 
(thiazide-type) in doses from 25mg to 
50mg and higher are associated with 
increased incidence of new-onset dia-
betes mellitus, particularly when com-
bined with high doses of beta-blockers 
(e.g. 100mg of atenolol).
A meta-analysis was recently pre-
sented of seven studies, in almost 
60,000 patients, showing that com-
pared to beta-blockers and diuretics, 
blockers of the renin-angiotensin sys-
tem decreased the occurrence of new 
onset diabetes by 20% (P <0.001) and 
calcium antagonists decrease onset of 
diabetes by 16% (P < 0.001).12
Another study reported a 16-year fol-
low-up of almost 800 initially untreated 
hypertensive patients of whom 6.5% 
had diabetes at the onset and 5.8% 
developed new onset diabetes on 
treatment. The risk for cardiovascular 
disease was similar in the group with 
pre-existing diabetes and the group 
who developed new-onset diabetes 
on treatment for hypertension.13 This 
suggests that the development of 
diabetes on antihypertensive treatment 
increases cardiovascular risk consider-
ably.  It could be that the combination 
of a low-dose diuretic with a blocker 
of the renin-angiotensin system or a 
calcium channel blocker may prevent 
the metabolic deleterious effect of a 
thiazide diuretic, as was shown with an 
ACE-inhibitor.14
See CPD Questionnaire, page 48
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SUMMARY OF TREATMENT:
1.  The goal Blood Pressure is 138/
80mmHg.
2.  Multiple drugs are best to 
achieve target.
3.  ACE-I (or ARB) should be part of 
the regimen.
4.  In T1DM with any degree of albu-
minuria an ACE-I is necessary.
5.  In T2DM with any degree of 
albuminuria an ARB is neces-
sary, especially with renal insuf-
ficiency.10
6.  Add a statin to reduce 
macrovascular risk.
IN CONCLUSION 
Hypertension treatment as part of a 
global cardiovascular risk reduction
Cardiovascular risk factors tend to 
cluster and insulin resistance, type 
2 diabetes mellitus, obesity and 
hypertension are commonly found in 
the same patient. Metformin, used to 
lower glucose, reduces cardiovascular 
risk in type 2 diabetes mellitus 
(T2DM) and also reduces the risk of 
a cardiovascular event in established 
macrovascular disease.15
British Guidelines suggest a reduction 
of LDL-cholesterol levels to <2mmol/L 
in T2DM patients
16 using a statin.  A 
meta-analysis of 12 randomised control 
clinical trials clearly demonstrated 
that in both primary and secondary 
prevention, diabetics had similar 
cardiovascular risk reductions than 
non-diabetics when using a statin.17 
The vast majority, if not all, T2DM 
patients should thus receive a statin. 
The aim of therapy is to reduce overall 
cardiovascular risk by targeting blood 
pressure reduction, blood sugar 
reduction and by routinely adding a 
statin in all diabetics. 
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